AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26524223 — intervention group
Group type: EXPERIMENTAL
Intervention: Capacitive mode of 448 kHz radiofrequency therapy
Number of subjects: 15
Study 26524223 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive mode of 448 kHz radiofrequency therapy
Number of subjects: 15
Study 23188377 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung transplantation
Number of subjects: 0
Study 21449990 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic instrumentation irrigated with essential oils (EOs)
Number of subjects: 64
Study 21449990 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic instrumentation irrigated with negative control
Number of subjects: 64
Study 18640992 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (morphine 1 mg/ml, nalbuphine 0 mg/ml)
Number of subjects: 311
Study 18640992 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (morphine 0.75 mg/ml, nalbuphine 0.25 mg/ml)
Number of subjects: 311
Study 18640992 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (morphine 0.5 mg/ml, nalbuphine 0.5 mg/ml)
Number of subjects: 311
Study 18640992 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4 (morphine 0.25 mg/ml, nalbuphine 0.75 mg/ml)
Number of subjects: 311
Study 18640992 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 5 (morphine 0 mg/ml, nalbuphine 1 mg/ml)
Number of subjects: 311
Study 16365183 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus IFL (irinotecan, fluorouracil, and leucovorin)
Number of subjects: 813
Study 16365183 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 813
Study 16365183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 813
Study 12809966 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg
Number of subjects: 21
Study 12809966 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir 600 mg
Number of subjects: 21
Study 12809966 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg and Ritonavir 600 mg
Number of subjects: 21
Study 11253328 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic CPB
Number of subjects: 132
Study 11253328 — intervention group
Group type: COMPARATOR
Intervention: Hypothermic CPB
Number of subjects: 132
Study 8888305 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral discrimination (one hand)
Number of subjects: 0
Study 8888305 — intervention group
Group type: COMPARATOR
Intervention: Bilateral discrimination (both hands)
Number of subjects: 0
Study 1848170 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous injection of inulin (70 mg/kg over 5 min)
Number of subjects: 47
Study 1848170 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection method
Number of subjects: 47
Study 6407314 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin
Number of subjects: 85
Study 6407314 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 85
Study 31887792 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereoscopic 3D AR model
Number of subjects: 58
Study 31887792 — intervention group
Group type: COMPARATOR
Intervention: Monoscopic 3D desktop model
Number of subjects: 58
Study 31887792 — intervention group
Group type: COMPARATOR
Intervention: 2D anatomical atlas
Number of subjects: 58
Study 30986760 — intervention group
Group type: EXPERIMENTAL
Intervention: Coloxyl with senna BD from day one (Regimen A)
Number of subjects: 570
Study 30986760 — intervention group
Group type: EXPERIMENTAL
Intervention: Coloxyl with senna +20 ml lactulose BD commencing on day 3 (Regimen B)
Number of subjects: 570
Study 30986760 — intervention group
Group type: EXPERIMENTAL
Intervention: Coloxyl with senna tablets +20 ml lactulose BD commencing on day 6 (Regimen C)
Number of subjects: 570
Study 30986760 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison of insertion rates across all regimens
Number of subjects: 570
Study 30986760 — intervention group
Group type: COMPARATOR
Intervention: Other major constipation‐ or diarrhea‐associated complications
Number of subjects: 570
Study 30986760 — intervention group
Group type: COMPARATOR
Intervention: Major patient‐centred outcomes
Number of subjects: 570
Study 30230517 — intervention group
Group type: EXPERIMENTAL
Intervention: High self-efficacy for exercise, absence of depressive symptoms, strong social support
Number of subjects: 31
Study 30230517 — intervention group
Group type: COMPARATOR
Intervention: RCAC residents
Number of subjects: 31
Study 30230517 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 31
Study 26194265 — intervention group
Group type: EXPERIMENTAL
Intervention: 27-Fr bougie
Number of subjects: 126
Study 26194265 — intervention group
Group type: COMPARATOR
Intervention: 39-Fr bougie
Number of subjects: 126
Study 24552888 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan-based treatment
Number of subjects: 8331
Study 24552888 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol-based treatment
Number of subjects: 8331
Study 24552888 — intervention group
Group type: EXPERIMENTAL
Intervention: Black race
Number of subjects: 8331
Study 22341603 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once daily
Number of subjects: 318
Study 22341603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study 19037719 — intervention group
Group type: EXPERIMENTAL
Intervention: Single session condom promotion Internet intervention
Number of subjects: 0
Study 19037719 — intervention group
Group type: COMPARATOR
Intervention: Control group (clinic sample)
Number of subjects: 0
Study 17187586 — intervention group
Group type: COMPARATOR
Intervention: ATI-7505 20 mg t.i.d.
Number of subjects: 36
Study 17187586 — intervention group
Group type: COMPARATOR
Intervention: ATI-7505 10 mg t.i.d.
Number of subjects: 36
Study 17187586 — intervention group
Group type: COMPARATOR
Intervention: ATI-7505 10 and 20 mg t.i.d.
Number of subjects: 36
Study 16318050 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam (xefocam, 16 mg/day)
Number of subjects: 140
Study 16318050 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac (ketanov, 60-90 mg/day)
Number of subjects: 140
Study 16318050 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen/ketonal (200 mg/day)
Number of subjects: 140
Study 16318050 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen/artrozilene (320 mg/day)
Number of subjects: 140
Study 16318050 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NSAIDs)
Number of subjects: 140
Study 11916781 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin combined with ephedrine (n = 19)
Number of subjects: 40
Study 11916781 — intervention group
Group type: COMPARATOR
Intervention: Ephedrine alone (n = 21)
Number of subjects: 40
Study 9475848 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-h euoxic hypercapnia
Number of subjects: 0
Study 9475848 — intervention group
Group type: COMPARATOR
Intervention: Control (air)
Number of subjects: 0
Study 7543180 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylometazoline hydrochloride (Otrivin Nasal Drops 0.1% or Pediatric Nasal Drops 0.05%)
Number of subjects: 72
Study 7543180 — intervention group
Group type: COMPARATOR
Intervention: Control group (only myringotomy and ventilation tube insertion)
Number of subjects: 72
Study 2366136 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin (10 million units intravenously) and tetracycline (0.25 g intramuscularly) for 12 hours
Number of subjects: 96
Study 2366136 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin (10 million units intravenously) and tetracycline (0.25 g intramuscularly) for 12 hours followed by oral ampicillin (2 g) and tetracycline (1.5 g) per day for 60 hours
Number of subjects: 96
Study 639708 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (80 mg, single daily dose) given on the 12th, 13th, and 14th day of digoxin treatment
Number of subjects: 20
Study 639708 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous administration of furosemide with beta-methyl-digoxin
Number of subjects: 20
Study 639708 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide given ten hours after the last digoxin dose
Number of subjects: 20
Study 31262691 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine treatment (group B2)
Number of subjects: 1745
Study 31262691 — intervention group
Group type: EXPERIMENTAL
Intervention: No treatment (group B1)
Number of subjects: 1745
Study 31262691 — intervention group
Group type: COMPARATOR
Intervention: Normal TSH levels (group A)
Number of subjects: 1745
Study 29045983 — intervention group
Group type: EXPERIMENTAL
Intervention: BATHE intervention (daily for five days or until discharge)
Number of subjects: 25
Study 29045983 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 25
Study 25496178 — intervention group
Group type: EXPERIMENTAL
Intervention: BNO 1016 (3 × 160 mg daily for 15 days)
Number of subjects: 589
Study 25496178 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 × placebo daily for 15 days)
Number of subjects: 589
Study 25496178 — intervention group
Group type: EXPERIMENTAL
Intervention: BNO 1016
Number of subjects: 589
Study 23808982 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban (10 mg twice daily for 7 days, followed by 5 mg twice daily for 6 months)
Number of subjects: 5395
Study 23808982 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (subcutaneous enoxaparin, followed by warfarin)
Number of subjects: 5395
Study 23808982 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 5395
Study 23808982 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 5395
Study 21981441 — intervention group
Group type: EXPERIMENTAL
Intervention: AWT(®) treatment with CELLACTOR(®) SC1 device, 8 sessions over 4 weeks
Number of subjects: 14
Study 21981441 — intervention group
Group type: EXPERIMENTAL
Intervention: AWT(®) treatment
Number of subjects: 14
Study 20112520 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride (NaF) administered for 6 months prior to stapedectomy.
Number of subjects: 2
Study 20112520 — intervention group
Group type: COMPARATOR
Intervention: Stapedectomy without sodium fluoride (NaF) administration.
Number of subjects: 2
Study 16929034 — intervention group
Group type: EXPERIMENTAL
Intervention: Full‐Serve version of McMaster PLUS
Number of subjects: 203
Study 16929034 — intervention group
Group type: COMPARATOR
Intervention: Self‐Serve version of McMaster PLUS
Number of subjects: 203
Study 16929034 — intervention group
Group type: EXPERIMENTAL
Intervention: Full‐Serve and Self‐Serve versions of McMaster PLUS
Number of subjects: 203
Study 15266196 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapeutic treatment
Number of subjects: 22
Study 15266196 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal cortisol levels
Number of subjects: 22
Study 15266196 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol response pattern during stress
Number of subjects: 22
Study 11642675 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 400 mg/kg body weight, total 30-45 g, administered in the follicular phase of a planned pregnancy, with a booster dose upon pregnancy diagnosis.
Number of subjects: 150
Study 11642675 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 150
Study 9373733 — intervention group
Group type: EXPERIMENTAL
Intervention: BRMs
Number of subjects: 51
Study 9373733 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 51
Study 8436740 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous urokinase alone
Number of subjects: 575
Study 8436740 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue-type plasminogen activator (rt-PA) alone
Number of subjects: 575
Study 8436740 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of intravenous urokinase and rt-PA
Number of subjects: 575
Study 8436740 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate catheterization
Number of subjects: 575
Study 8436740 — intervention group
Group type: COMPARATOR
Intervention: Deferred catheterization
Number of subjects: 575
Study 8436740 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin specificity
Number of subjects: 575
Study 3108758 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 60
Study 3108758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 29511020 — intervention group
Group type: EXPERIMENTAL
Intervention: Temstem+AVH monitoring
Number of subjects: 100
Study 29511020 — intervention group
Group type: COMPARATOR
Intervention: AVH monitoring
Number of subjects: 100
Study 26615328 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanoliposomal irinotecan plus fluorouracil and folinic acid
Number of subjects: 417
Study 26615328 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanoliposomal irinotecan monotherapy
Number of subjects: 417
Study 26615328 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil and folinic acid
Number of subjects: 417
Study 24849843 — intervention group
Group type: EXPERIMENTAL
Intervention: Response-adaptive randomization scheme with minimal sufficient balancing design for baseline covariates and a cap on treatment allocation ratio shift.
Number of subjects: 0
Study 24849843 — intervention group
Group type: COMPARATOR
Intervention: Control of important covariate imbalance and protection of treatment allocation randomness.
Number of subjects: 0
Study 22747248 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 33
Study 22747248 — intervention group
Group type: COMPARATOR
Intervention: Sham-acupuncture
Number of subjects: 33
Study 19996730 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation
Number of subjects: 0
Study 19996730 — intervention group
Group type: COMPARATOR
Intervention: Traditional chemotherapy
Number of subjects: 0
Study 19996730 — intervention group
Group type: COMPARATOR
Intervention: Targeted therapy
Number of subjects: 0
Study 18481113 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CSA) 150 mg/m(2) orally to achieve trough levels of 120-180 ng/ml
Number of subjects: 32
Study 18481113 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide pulses (CPH) 500 mg/m(2) per month intravenous
Number of subjects: 32
Study 16136855 — intervention group
Group type: EXPERIMENTAL
Intervention: RSR13 (100 mg/kg)
Number of subjects: 7
Study 16136855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 16136855 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 7
Study 11802257 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention
Number of subjects: 616
Study 11802257 — intervention group
Group type: COMPARATOR
Intervention: Attention-control intervention
Number of subjects: 616
Study 10075142 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg twice daily
Number of subjects: 1054
Study 10075142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1054
Study 7677456 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 169
Study 7677456 — intervention group
Group type: COMPARATOR
Intervention: Open appendectomy
Number of subjects: 169
Study 2251872 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine with pertussis toxoid
Number of subjects: 0
Study 2251872 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine with pertussis toxoid and filamentous haemagglutinin
Number of subjects: 0
Study 2251872 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated children
Number of subjects: 0
Study 7423302 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal fetal movements
Number of subjects: 135
Study 7423302 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal HPL levels
Number of subjects: 135
Study 7423302 — intervention group
Group type: EXPERIMENTAL
Intervention: Both abnormal fetal movements and abnormal HPL levels
Number of subjects: 135
Study 6681470 — intervention group
Group type: EXPERIMENTAL
Intervention: Phasic vergence training (stepwise tasks)
Number of subjects: 34
Study 6681470 — intervention group
Group type: COMPARATOR
Intervention: Tonic vergence training (smooth, slow activities)
Number of subjects: 34
Study 31091754 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen peptide supplementation (15 g daily)
Number of subjects: 25
Study 31091754 — intervention group
Group type: COMPARATOR
Intervention: Resistance exercise training (RET)
Number of subjects: 25
Study 29300387 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-genome sequencing (WGS) results
Number of subjects: 202
Study 29300387 — intervention group
Group type: COMPARATOR
Intervention: Family health history (FH) information alone
Number of subjects: 202
Study 26864325 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer interpretation messages (correct interpretation)
Number of subjects: 254
Study 26864325 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer interpretation messages (incorrect interpretation)
Number of subjects: 254
Study 26864325 — intervention group
Group type: EXPERIMENTAL
Intervention: Correct computer interpretations
Number of subjects: 254
Study 26864325 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorrect computer interpretations
Number of subjects: 254
Study 25131042 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Group (EG) - 24 sessions of continuous 30 min treadmill exercise, intensity increased from 50%-70% of maximum heart rate.
Number of subjects: 15
Study 25131042 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - No exercise intervention.
Number of subjects: 15
Study 22234928 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (ARIP; 5-30 mg/day)
Number of subjects: 52
Study 22234928 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (ZIP; 40-160 mg/day)
Number of subjects: 52
Study 20800189 — intervention group
Group type: EXPERIMENTAL
Intervention: Online spaced education
Number of subjects: 724
Study 20800189 — intervention group
Group type: COMPARATOR
Intervention: Web-based teaching (WBT)
Number of subjects: 724
Study 17875084 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E at a dose of 100 mg/day for 3 months
Number of subjects: 58
Study 17875084 — intervention group
Group type: COMPARATOR
Intervention: No medication (control group)
Number of subjects: 58
Study 16213237 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based physical therapy (PT) group (n=13)
Number of subjects: 25
Study 16213237 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=12)
Number of subjects: 25
Study 11908582 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography (US) of the hip
Number of subjects: 24
Study 11908582 — intervention group
Group type: COMPARATOR
Intervention: Control group (no history of hip joint or rheumatic disease)
Number of subjects: 24
Study 10100994 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrpulmonary instillation of 2.6 microm-diameter iron oxide particles
Number of subjects: 0
Study 7762370 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60
Study 7762370 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 60
Study 7762370 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine
Number of subjects: 60
Study 2218196 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched design
Number of subjects: 0
Study 2218196 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline smoking quit rates
Number of subjects: 0
Study 7010522 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-5-aminosalicylic acid (Ac-5-ASA) retention enemas
Number of subjects: 40
Study 7010522 — intervention group
Group type: COMPARATOR
Intervention: Dummy enemas (placebo)
Number of subjects: 40
Study 31532959 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypill (atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, hydrochlorothiazide 12.5 mg)
Number of subjects: 303
Study 31532959 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 303
Study 29223666 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 126
Study 29223666 — intervention group
Group type: COMPARATOR
Intervention: Open appendectomy (OA)
Number of subjects: 126
Study 27552065 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga practice for 8 weeks
Number of subjects: 15
Study 23570583 — intervention group
Group type: EXPERIMENTAL
Intervention: Major Depressive Episodes (MDEs)
Number of subjects: 137
Study 23570583 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial or full remission
Number of subjects: 137
Study 23570583 — intervention group
Group type: EXPERIMENTAL
Intervention: No or active substance abuse
Number of subjects: 137
Study 23570583 — intervention group
Group type: EXPERIMENTAL
Intervention: Current MDE
Number of subjects: 137
Study 21837534 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg once daily plus phloroglucinol
Number of subjects: 150
Study 21837534 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg plus phloroglucinol
Number of subjects: 150
Study 21837534 — intervention group
Group type: COMPARATOR
Intervention: Phloroglucinol 240 mg daily (Control Group)
Number of subjects: 150
Study 19671145 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy (1-hour session, 4 times a week for 10 weeks) plus pharmacological therapy
Number of subjects: 24
Study 19671145 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological therapy only
Number of subjects: 24
Study 17067857 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-randomization for optimal dosing
Number of subjects: 65
Study 17067857 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-randomization for optimal dose-scheduling
Number of subjects: 65
Study 17067857 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-randomization for salvage therapy
Number of subjects: 65
Study 17067857 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct comparison trials
Number of subjects: 65
Study 17067857 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard efficacy trials
Number of subjects: 65
Study 17067857 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of treatment trials
Number of subjects: 65
Study 17067857 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient loss from period 1 to period 2
Number of subjects: 65
Study 15745869 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 65